# Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape

## TL;DR

Bispecific antibodies show promise in treating glioblastoma by targeting both tumor cells and immune cells, improving immune response and overcoming tumor defenses.

## Contribution

The paper highlights mechanistic advances and delivery innovations in bispecific antibodies for glioblastoma immunotherapy.

## Key findings

- BsAbs can cross the blood-brain barrier and modulate the immunosuppressive tumor environment.
- BsAbs outperform traditional therapies by redirecting immune cells and blocking immune checkpoints.
- BsAbs face challenges in delivery efficiency and immune-related adverse events but offer enhanced therapeutic precision.

## Abstract

The application of bispecific antibody (BsAbs)-based therapeutic strategies for glioblastoma (GBM) has shown considerable promise. By concurrently targeting tumor-associated antigens and immune effector cells, BsAbs can traverse the blood-brain barrier, modulate the immunosuppressive tumor microenvironment, and surmount challenges such as intratumoral heterogeneity and immune evasion. Accumulating evidence indicates that BsAbs surpass conventional monoclonal antibodies and chimeric antigen receptor T cell therapies in the context of GBM through mechanisms that include the redirection of immune cells, blockade of immune checkpoints, and synergistic inhibition of oncogenic signaling pathways. Although constrained by limitations in intracerebral delivery efficiency and the potential for immune-related adverse events, BsAbs represent a promising new frontier in GBM immunotherapy. They particularly enhance therapeutic precision and durability, underscoring their potential as a transformative approach for managing this aggressive malignancy.